Editas Medicine (EDIT) Research & Development (2016 - 2025)
Historic Research & Development for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $19.8 million.
- Editas Medicine's Research & Development fell 5848.99% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year decrease of 4951.68%. This contributed to the annual value of $199.2 million for FY2024, which is 1215.64% up from last year.
- Editas Medicine's Research & Development amounted to $19.8 million in Q3 2025, which was down 5848.99% from $16.2 million recorded in Q2 2025.
- Over the past 5 years, Editas Medicine's Research & Development peaked at $69.6 million during Q4 2023, and registered a low of $16.2 million during Q2 2025.
- Moreover, its 5-year median value for Research & Development was $40.5 million (2023), whereas its average is $39.8 million.
- In the last 5 years, Editas Medicine's Research & Development skyrocketed by 8204.1% in 2024 and then tumbled by 7015.13% in 2025.
- Over the past 5 years, Editas Medicine's Research & Development (Quarter) stood at $37.6 million in 2021, then surged by 38.47% to $52.0 million in 2022, then soared by 33.77% to $69.6 million in 2023, then plummeted by 30.11% to $48.6 million in 2024, then crashed by 59.32% to $19.8 million in 2025.
- Its last three reported values are $19.8 million in Q3 2025, $16.2 million for Q2 2025, and $26.6 million during Q1 2025.